In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLD C/S ) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD results in enhanced cell proliferation and inhibition of apoptosis; it also stimulates cell migration and induces the expression of angiogenic factors, including vascular endothelial growth factor-A. Altogether, these characteristics indicate an increased oncogenicity of the tumorigenic epidermal CYLD C/S mutant cells in vitro. Moreover, we show the increase in malignancy of epidermal squamous cell carcinomas that express the CYLD C/S transgene in an in vivo xenograft model. Tumors carrying the mutated CYLD C/S exhibit a fast growth, are poorly differentiated and present a robust angiogenesis. CYLD C/S tumors are also characterized by their elevated proliferation rate and decreased apoptosis. In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy.
Introduction
Cyld encodes a 956-amino acid enzyme (CYLD) that is ubiquitously expressed and contains a deubiquitinating domain at the C-terminus, which removes lysine 63 linked polyubiquitin chains from distinct members of the nuclear factor (NF)-kB pathway (Brummelkamp et al., 2003; Kovalenko et al., 2003; Regamey et al., 2003; Trompouki et al., 2003) . CYLD negatively regulates NF-kB activation, and mutations that inactivate the carboxyl-terminal deubiquitinating domain of CYLD deregulate the NF-kB activity, underlying the development of skin appendage tumors in humans (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003) . CYLD was originally identified as a gene mutated in familial cylindromatosis (FC), a genetic condition that predisposes patients for the development of cylindromas, benign tumors that typically appear on the scalp (Bignell et al., 2000) . Cylindromatosis patients carry heterozygous germ-line mutations in the carboxyl-terminal end of the CYLD gene, but the wild-type CYLD allele undergoes loss of heterozygosity, indicating that CYLD appears as a tumor-suppressor gene (Bignell et al., 2000) . Cylindromas are usually benign, although occasionally they can malignize (Durani et al., 2001; De Francesco et al., 2005) . Additional studies have associated Cyld downregulation with the development of other types of human cancer including tumors of colon, lung and kidney, as well as melanomas and cervical and hepatocellular carcinomas (Strobel et al., 2002; Hashimoto et al., 2004; Hirai et al., 2004; Costello et al., 2005; Hellerbrand et al., 2007; Keats et al., 2007; Zhong et al., 2007; Massoumi et al., 2009 ). In the case of multiple myeloma and melanoma, it has been shown that its grade of malignancy is directly related with the silencing of CYLD, being of poor prognosis those tumors with lower expression level of CYLD (Annunziata et al., 2007; Jenner et al., 2007; Massoumi et al., 2009) .
Depending on the external signals, CYLD negatively regulates different NF-kB pathways: inactivation of TRAF2 or TRAF6 causes survival and inflammation because of the classical NF-kB constitutive activation (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003) whereas inhibition of Bcl-3 controls proliferation and tumor growth. Thus, mice deficient in CYLD are more susceptible to develop chemically induced skin tumors (Massoumi et al., 2006; Massoumi and Paus, 2007) . In this case, the loss of CYLD in keratinocytes was linked to hyperproliferation and elevation in cyclin D1 levels because of increased nuclear activity of Bcl-3-associated NF-kB p50 and p52 and is independent of the classical p65/NF-kB pathway (Massoumi et al., 2006) . These investigators reported that in the case of non-melanoma skin cancer (NMSC) the analysis by microarrays of different types of human tumors suggests that there is a relationship between the level of CYLD expression and the grade of malignancy of the tumor: CYLD is clearly detected in normal skin, less expressed in benign basal cell carcinomas and poorly detected in malignant squamous cell carcinomas (SCCs) (Massoumi et al., 2006) . However, the relationship between CYLD silencing and worsening of tumors is not so firmly established in NMSC as in melanomas (Massoumi et al., 2009) .
The incidence of both benign and malignant skin neoplasms has been rising at an alarming rate for the past several years. NMSC is one of the most common malignancies in humans: basal cell carcinomas and SCCs represent the vast majority of the tumors diagnosed (Limmer, 2001) . NMSC are believed to arise from stem cells of the hair follicles and their growth and development seems to rely on an early burst of neovascularization in which vascular endothelial growth factor-A (VEGF-A) is the main and most powerful factor involved (Larcher et al., 1996 (Larcher et al., , 1998 Detmar, 2000a) .
To obtain a deeper understanding for possible skin SCCs therapies, it is important to find the signalling proteins involved in the progression of these carcinomas. Here, we have focused our attention to the study of the possible involvement of CYLD in skin tumor progression, as this gene has been implicated in the progression of different cancer cell types such as melanoma, colon, hepatocellular and multiple myeloma (Annunziata et al., 2007; Hellerbrand et al., 2007; Jenner et al., 2007; Massoumi et al., 2009) .
In this study, we demonstrate that the expression of a catalytically inactive mutant form of CYLD (CYLD C/S ) in tumorigenic epidermal cells diminished the deubiquitinating activity of the endogenous CYLD, resulting in increased expression of several angiogenic factors, including VEGF-A, and accelerated proliferation and migration of tumoral cells, enhancing tumor progression.
Results

Effects of the catalytically inactive CYLD
C/S mutant in the PDVC57 tumorigenic epidermal cells To explore the consequences of the expression of a mutant CYLD (defective in the deubiquitinating function) in tumoral epidermal cells, we introduced the mutant CYLD C/S complementary DNA in the PDVC57 cell line. This mutant carries the 601 C/S point mutation in the cysteine box of the deubiquitinase domain, resulting in a catalitically inactive protein that is able to compete with the endogenous CYLD (Brummelkamp et al., 2003; Trompouki et al., 2003; Massoumi et al., 2006 Massoumi et al., , 2009 . The PDVC57 cells were chosen because they bear a Ha-ras mutation carried by all the chemically induced mouse skin tumors and some human skin carcinomas (Pierceall et al., 1991; Spencer et al., 1995) . PDVC57 cells were stably transfected with the mouse CYLD C/S complementary DNA tagged with a hemagglutinin-A epitope under the control of the b-actin promoter ( Figure 1a ) or with the empty vector. Pooled stable transfectans from approximately 60 different colonies were used to minimize any potential effect of clonal selection. They were designated as C57-CYLD C/S and compared with C57-Control cells (expressing the CYLD C/S transgene and the empty vector respectively). Western blotting against hemagglutinin-A and CYLD showed that C57-CYLD C/S cells expressed the transgene and had increased levels of CYLD (Figure 1b We analyzed the activation of the canonical NF-kB pathway by measuring the active form of NF-kB in cellular extracts from each cell type and found that CYLD C/S caused an increase in NF-kB activity both in the basal, unstimulated state of the C57-CYLD C/S cells as well as after TNF-a stimulation (Figure 1d ). The increased NF-kB activity in mutant cells is in agreement with the increased levels of P-p65 detected in these cells (Figure 1b) . Therefore, the expression of a catalytically inactive CYLD in PDVC57 cells resulted in a diminished deubiquitination function and subsequent elevated activation of the classical NF-kB pathway.
CYLD
C/S enhances the proliferation of tumorigenic epidermal cells We examined a number of growth properties of C57-CYLD C/S cells in monolayer cultures. Growth curves show that after 48 h of culture the growth profile of the CYLD C/S cells experience a rapid increase in cell number (Figure 2a ) that is accompanied by a significantly enhanced proliferation (Figure 2b ). When the colonyforming efficiency was examined, we found that both types of cells formed a similar number of colonies. However, significant differences were found in colony size, that is, while most of the colonies in control cultures had o1 mm of diameter, the majority of the C57-CYLD C/S colonies were of greater size (2-4 mm), indicating their increased long-term proliferation (Figure 2c ). This result is in agreement with the increased rate of BrdU incorporation detected in the C57-CYLD C/S cells ( Figure 2b ). As a measure of cell proliferation we also compared cyclin D1 expression in cells of both genotypes (72 h of culture), finding that it was increased in the C57-CYLD C/S cells ( Figure 1b ). CYLD C/S promotes a mesenchymal phenotype and enhances the migration of the C57-CYLD C/S cells Although C57-Control cells displayed an epithelial morphology, with abundant cell-to-cell interactions, C57-CYLD C/S cells were more scattered and exhibited a mesenchymal spindle-shaped phenotype with limited intercellular contacts (Figure 2d ). Accordingly, we found changes in E-cadherin distribution. In C57-Control cells, it was predominantly detected as a continuous line at cell-cell contacts. However, it was irregularly distributed in a pattern of dots or aggregates in most C57-CYLD C/S cells ( Figure 2d ). The effect of the expression of CYLD C/S on C57 cell motility was therefore evaluated by an in vitro wound healing assay. Cells growing in monolayer cultures were subjected to a 'scratch' wound. On scratching, C57-CYLD C/S cells formed large and abundant foci of migration while C57-Control cells formed scarce and small foci along the 'scratch' wound ( Figure 2e ).
C/S enhances the survival of malignant epidermal cells In addition to increased cell proliferation and migration, another marker of malignant progression of tumoral cells is their anchorage-independent growth (Evan and Littlewood, 1998; Hanahan and Weinberg, 2000; Green and Evan, 2002) . The effect of the expression of CYLD C/S on the anchorage-independent growth of C57 cells was examined in suspension cultures. We found that CYLD C/S leads to a significant survival of C57 cells after 24-h growing in suspension ( Figure 3a) .
We next studied the effect of the expression of CYLD C/S on the survival of C57 cells maintained in serum-deprived medium. The number of cells that survive in serum-free cultures was higher in C57-CYLD C/S than in C57-Control cultures ( Figure 3b ). Cleaved caspase3 immunostaining showed a significantly larger percentage of cells that undergo apoptosis in the C57-Control cultures grown in absence of serum than in C57-CYLD C/S cells ( Figure 3c ). Similarly, western blot analysis showed a diminished expression of cleaved caspase-3 in the C57-CYLD C/S cells ( Figure 3d ). The expression of other pro-apoptotic molecule, Bax, was also reduced in the C57-CYLD C/S cells ( Figure 3d ). It is intriguing that the expression of Bax does not precede that of caspase 3 as it happens in the intrinsic apoptosis pathway. However, it has been recently shown that apoptosis may occur in a Bax-dependent-caspase 3-independent manner as well as in Bax-independentcaspase-dependent pathway (Li et al., 2009; Scharstuhl et al., 2009; Zhang et al., 2010) . Overall, our results indicate that the expression of CYLD C/S in PDVC57 cells turns the cells more resistant to apoptosis under stress conditions, probably through inhibition of the expression of pro-apoptotic genes. Catalytically inactive CYLD promotes skin tumor progression JP Alameda et al CYLD C/S induces the expression of angiogenic factors and oncogenic proteins in tumoral epidermal cells One of the factors that determine an increased survival of cells in suspension is the expression of VEGF-A (Solovey et al., 1999) . We found that C57-CYLD C/S cells secrete higher levels of VEGF-A than C57-Control cells (Figure 3e ). To analyze whether this is a specific property of the C57 cells or, on the contrary, whether CYLD C/S also enhances the VEGF-A expression in other epidermal cells of different condition (tumoral or non-tumoral) and species, we transfected the nontumorigenic human keratinocyte HaCaT cell line, and the murine PB transformed epidermal cells with the b-actin-CYLD C/S construct. Pools of colonies constitutively expressing the CYLD C/S were isolated and the expression level of angiogenic factors analyzed by northern blot (Figure 3f and Table 1 ). It was observed that VEGF-A expression was enhanced in all cell lines expressing the CYLD C/S construct (Table 1) irrespective of its origin (human or mouse) or its state (tumoral or non-tumoral). Other angiogenic factors, such as thrombospondins TSP-1 and TSP-2 were also induced in cells expressing the mutated form of CYLD (Figure 3f ; see the quantification in Table 1 ).
As increased VEGF-A expression promotes tumoral angiogenesis and subsequent oncogenicity (Ferrara, 2002; Carmeliet, 2003; Ferrara et al., 2003) , we analyzed the expression of oncogenic molecules such as Bcl3 and b-catenin, which has been found to be oncogenic when located in the nucleus (Cogswell et al., 2000; Thornburg et al., 2003; Moon et al., 2004; Clevers, 2006) . Our results show an important increase in the total amount of both proteins (Figure 1b) and their preferential nuclear localization in the C57-CYLD C/S cells (Figure 3g ). The increase in nuclear Bcl3 and b-catenin expression was accompanied by an increase in nuclear p52 in the mutant cells as it has been previously reported (Massoumi et al., 2006) . 
Catalytically inactive CYLD promotes skin tumor progression JP Alameda et al
The expression of CYLD C/S in tumoral epidermal cells increases the malignancy of skin carcinomas To determine whether the expression of the mutated CYLD C/S in tumor epidermal cells also enhances tumorigenicity in vivo, we used a xenograft model of PDVC57 cells injected subcutaneously into immunodeficient mice.
The latency of macroscopic tumor appearance was approximately 1 week in the C57-CYLD C/S tumors and 2 weeks in C57-Control tumors. Mutant tumors exhibited a very fast growth (Figure 4a ). Tumors were harvested 17 days after injection. At this time C57-Control cells gave rise to relatively small and pale tumors. In contrast, C57-CYLD C/S cells developed into larger tumor masses with a distinctive red appearance suggestive of a robust vascularization ( Figure 4b) ; the size of the mutant tumors was on average B6-fold greater than that of the controls (Figures 4a and b) . We verified by western blot the expression of the transgene in tumors originated by C57-CYLD C/S cells (Figure 5d ). Histopathological examination of tumors showed that while Control tumors were differentiated SCCs with frequent appearance of keratin pearls (Figure 4c ), tumors originated from C57-CYLD C/S cells were poorly differentiated SCCs (Figure 4c ). Immunohistochemical analysis of the expression pattern of distinct differentiation markers further corroborated this diagnosis. Thus, C57-Control tumors expressed elevated levels of keratins K1 and K10-reliable markers of well-differentiated tumors. By contrast, in accordance with their poorly differentiated phenotype, C57-CYLD C/S SCCs showed scarce expression of K1 and K10, limited to isolated cells (Figure 5a and data not shown). On the contrary, keratin K8, a marker of malignancy in skin tumors (Casanova et al., 2004) showed extensive staining in the C57-CYLD C/S carcinomas and weak expression in the C57-Control tumors (Figure 5a ). K13, a keratin characteristic of internal stratified squamous epithelia, which is aberrantly expressed in skin tumors and is also considered a marker of tumor progression (Winter et al., 1990; Moreno-Maldonado et al., 2008) was also highly expressed in the C57-CYLD C/S tumors and it was hardly detected in the C57-Control SCCs (Figure 5a ). These data confirm that the tumors arising from C57-CYLD C/S cells are more aggressive that those from control cells. ( Figure 5d ). Together, these results suggest that the expression of CYLD increases epidermal tumor promotion by enhancing both tumor cell proliferation and survival.
CYLD C/S enhances angiogenesis in skin carcinomas
The red appearance of the C57-CYLD C/S SCCs pointed to a strong blood supply that could also explain the enhanced growth of these carcinomas. We therefore analyzed at the cellular and molecular levels the changes in vascularization produced by the expression of the mutant CYLD in skin tumors derived from C57-CYLD C/S and C57-Control cells. Northern blot analysis showed that the expression of VEGF-A, TSP-1 and TSP-2 was enhanced in the CYLD C/S tumors (Figure 6b ; see the quantification in Table 2 ). Immunostaining of CD31, a marker of endothelial cells showed in control tumors a blood vessels pattern characterized predominantly by narrow and small capillaries; by contrast, CYLD C/S carcinomas showed a network of large and lacunar vessels (Figure 6a ). We next examined whether these changes in tumor vascularization led to substantial differences in vascular functionality. Tumor-bearing animals were anesthetized and a dye (Evans blue) was injected into the tail vein. We found that dye accessibility to the tumors was much higher in C57-CYLD C/S carcinomas than in C57-Control tumors (Figure 6c ). These observations indicate that the vascular network of actively growing C57-CYLD C/S carcinomas is large, plastic and leaky whereas that of the slowly growing C57-Control tumors is smaller and impermeable.
Discussion
Our studies indicate that a decrease in CYLD function results in an increase in the malignant behavior of the tumor epidermal cells and in the progression of skin carcinomas, as seen by an enhancement in proliferation and survival of the cells expressing the mutant CYLD C/S . This could be explained by the higher NF-kB activity found in the C57-CYLD C/S cells, in line with the findings indicating that malignant epidermal cells have accumulated molecular alterations that enable a 'switch' of NFkB function from being a tumor suppressor in normal murine and human keratinocytes (Seitz et al., 1998; van Hogerlinden et al., 1999; Dajee et al., 2003) to being a tumor promoter (Ren et al., 2006) . Tumor epidermal cells expressing CYLD C/S also show an important increase in the nuclear localization of Bcl3, p52 and b-catenin. We also find an increase in cyclin D1 expression, likely because of the increase in nuclear Bcl3/p52. This could also explain the increased proliferation and enhanced aggressiveness of C57-CYLD C/S cells, as activated nuclear Bcl3/p50/p52 expression has been shown to promote cell proliferation and oncogenesis through the activation of the cyclin D1 gene in breast and nasopharyngeal human tumors (Cogswell et al., 2000; Thornburg et al., 2003) . Increased nuclear localization of p50/p52 and Bcl3 was also found in advanced stages of mouse skin carcinomas (Budunova et al., 1999) . Nuclear Bcl3 has been detected in cylindroma cells, whereas normal skin keratinocytes retain Bcl3 in the cytoplasm (Massoumi et al., 2006 ). An increase in nuclear Bcl3 accumulation and transcription of cyclin D1 was also observed in CYLD-deficient keratinocytes (Massoumi et al., 2006) . Our results show that CYLD C/S may also favor the malignancy of the epithelial cells by promoting mesenchymal features, such as the fibroblast-like morphology, delocalized E-cadherin expression and increased migration. In addition, we have corroborated in vivo the enhanced malignancy of C57-CYLD C/S cells, in a xenograft model of skin carcinogenesis and we checked that in another tumor epidermal cell line (PB cells), CYLD C/S also increases the aggressiveness of both cells and tumors originated in xenograft assays (Alameda et al., unpublished results) .
Notably, our findings reveal a yet unknown link between VEGF-A and CYLD in epidermal cells and skin tumors. We have demonstrated that a decrease in CYLD catalytic activity results in a striking induction of VEGF-A expression both in tumoral and non-tumoral keratinocytes, as well as in skin carcinomas. It is well established that VEGF-A is the main angiogenic factor involved in physiologic and pathologic skin processes including wound healing, ultraviolet response, psoriasis and tumorigenesis (Ferrara, 2000; Detmar, 2000a, b) . In the case of skin cancer, VEGF-A overexpression in murine epidermis predisposes mice to tumor development (Larcher et al., 1998; Detmar, 2000b) , and very recently it has been reported that VEGF-A has a relevant role not only in the first stage of neoangiogenesis establishment but also in the advanced stages of tumor progression of several malignancies, including NMSC (Mirones et al., 2009) .
Our data indicate that besides the high proliferation rate and reduced apoptosis, enhanced growth of C57-CYLD C/S tumors may also be due to the induction of angiogenesis, as in addition to their increased VEGF-A Catalytically inactive CYLD promotes skin tumor progression JP Alameda et al expression, C57-CYLD C/S tumors also develop large and lacunar blood vessels, a prominent feature of skin tumor progression . It will be interesting to test whether the induction of VEGF-A expression also takes place in human neoplasias associated with a reduced expression of CYLD (such as colon, lung, kidney, cervical and hepatocellular carcinomas).
Our results show an increase in nuclear accumulation and then activation of b-catenin when the function of CYLD is diminished in C57-CYLD C/S cells. This finding has been very recently corroborated by a work, which describes that loss of CYLD impairs K63-deubiquitination of Dvl enhancing Wnt-induced accumulation of nuclear b-catenin (Tauriello et al., 2010) . Constitutive bcatenin activation has been documented in several human cancers. In the case of human colon carcinomas, activating mutations have been described (Kinzler and Vogelstein, 1996) . However, in multiple myeloma and other hematologic malignancies, no mutations have been identified in the Wnt/b-catenin pathway, indicating alternative mechanisms for b-catenin activation (Derksen et al., 2004; Qiang et al., 2005; Sukhdeo et al., 2007) . Interestingly CYLD expression is downregulated in multiple myeloma (Annunziata et al., 2007) , suggesting that similarly to our model, reduced CYLD activity could cause activation of b-catenin in this type of cancer.
Our results showing the increased malignancy of skin tumors by a reduction in CYLD function are in agreement with observations indicating that CYLD expression is reduced in benign basal cell carcinomas and absent in malignant SCCs (Massoumi et al., 2006) . However, in contrast with our findings, cyldÀ/À mice exhibit increased susceptibility to the development of skin cancer, although no signs of malignancy were found in those tumors developed (Massoumi et al., 2009) . The reason could be that in our model, the acquired mutation in CYLD is posterior to a preexisting ras-mutation in the epidermal cells, instead of constituting the only mutagenic event, as in the cyldÀ/À mice model. In the case of melanoma, in which it has been described that reduced levels of CYLD promote the aggressiveness of the tumors, the reduction in CYLD expression also takes place after previous mutation/s have caused the tumor development (Massoumi et al., 2006) . This could explain why malignization of cylindromas in patients of FC occurs with very low frequency (Durani et al., 2001; De Francesco et al., 2005) ; it could be due to the early age of outcome of the disease (from childhood to the second decade of the life) when previous mutations have not had time to occur in these patients.
Therefore, on the basis of our observations, we propose a model wherein the diminished function of CYLD confers aggressive characteristics to already tumorigenic epidermal cells, enhancing cell proliferation, migration, survival and angiogenesis. Moreover, in addition to the role of CYLD in the regulation of the canonical NF-kB signaling pathway and the p52-Bcl3-dependent activation, we have established that CYLD has an important role in tumor progression by regulating the expression of angiogenic factors and b-catenin nuclear localization.
Materials and methods
Cell lines and culture conditions PDVC57, HaCaT and PB cells were cultured in Dulbecco's modified Eagle's medium (DMEM)-10% fetal calf serum; transfected using the calcium phosphate method and selected using G418 (0.45 mg/ml).
DNA constructs CYLD C/S complementary DNA was kindly provided by Dr R Bernards and subcloned under the b-actin promoter. b-actincontrol construct has been described (Frederickson et al., 1989) .
Cell proliferation assay 5 Â 10 4 cells per p60 were seeded in complete medium. At 24, 48, 72 and 96 h cells were trypsinized and counted in a Neubauer chamber. Experiments were repeated three times.
Cell suspension growth
Multiwell plates were covered with 0.9% agarose in DMEM. After 1 h, 3 Â 10 5 cells were added. After 24 h, multiwells were seeded with 600 ml aliquots of the cellular suspension and feeded with DMEM-10% fetal bovine serum for 48 h.
Growth in serum-free medium Cells were seeded into p60-plates in complete medium. After 24 h, the medium was replaced by serum-free DMEM. Cells were observed daily during 6 days.
Wound healing assay Cells growing in monolayer cultures were incubated 2 h in DMEM plus 5 mg/ml of mitomycin C, and then washed with PBS. After 1 h, a 'scratch' wound was created in vitro by scraping the cell monolayer with a sterile pipette tip.
Colony-forming assay A total of 3 and 6 Â 10 2 cells were seeded per duplicate in DMEM-10% fetal bovine serum in p100 plates. Media were replaced every 4 days.
Northern blotting
Total RNA was isolated using TRIzol (Molecular Research Center Inc., Cincinnati, OH, USA) following manufacturer's instructions. In all, 20 mg/lane of RNA were probed for the expression of VEGF-A, Tsp-1 and Tsp-2 (Casanova et al., 2002) .
Enzyme-linked immunosorbent assay
Secreted VEGF-A isoform was measured in culture medium by enzyme-linked immunosorbent assay using a commercial kit, following manufacturer's instructions (Quantikine Mouse VEGF Immunoassay; R&D Systems, Minneapolis, MN, USA).
Xenograft model of skin carcinogenesis
Tumors were induced in nude mice (Hsd-Athymic Nude, Harlan, Barcelona, Spain) by subcutaneous flank inoculation of 10 6 PDVC57 Control or -CYLD C/S cells. Experimental procedures were performed according to European and Spanish laws.
Vascular permeability assay
Plasma leakage was determined using Evans blue dye as previously described (Thurston et al., 1998) .
Abbreviations NMSC, non-melanoma skin cancer; HA, hemagglutinin-A.
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